Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2022-12-06 07:00:00
Following the recent publication of its analysis of Newbury Pharmaceuticals, Redeye will host two events where Newbury Pharmaceuticals, CEO, Lars Minor will explain more about the strategy and answer questions to the analysis
The events will be hosted by Redeye and take place online on the 14th December and in Gothenburg on the 15th December. Please visit https://www.redeye.se/events for more information about the two events.
Redeye published its analysis of Newbury Pharmaceuticals with the below summary.
“Redeye initiates coverage of Newbury Pharmaceuticals, a hybrid pharmaceutical company focusing on providing specialty and branded products on the Scandinavian markets. We identify rapid growth opportunities rooted in an exciting pipeline, bolstered by strong management with extensive sector expertise. We argue that the share offers de-risked exposure to an ever-growing pharmaceutical market and see several potential catalysts ahead”.